Keyword: Phenex Pharmaceuticals

Gilead's NASH prospects firsocotat and cilofexor failed to move the needle on liver scarring in a phase 2 study, on their own or in combination.

Gilead unveiled phase 2 data showing its FXR agonist improved liver biochemistry and cholestasis in patients with primary sclerosing cholangitis.

Pfenex's CEO resigned after an in-house investigation found him in breach of company code in third-party contracts, and Kymab recruited drug development vet Schottelius as EVP.